Discounted Cash Flow (DCF) Analysis Levered

Relmada Therapeutics, Inc. (RLMD)

$2.85

0.00 (0.00%)
Financial Summary
Financial Statements
Quarter Financials
Chart
Financial Ratios
Profile
Historical Data
DCFDCF Levered
All numbers are in Millions, Currency in USD

Free Cash Flow

Year
A/P
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Revenue ----------
Revenue (%)
Operating Cash Flow ----------
Operating Cash Flow (%)
Capital Expenditure ----------
Capital Expenditure (%)
Free Cash Flow ----------

Weighted Average Cost Of Capital

Share price $ 2.85
Beta 0.162
Diluted Shares Outstanding 29.63
Cost of Debt
Tax Rate 0.00
After-tax Cost of Debt 5.00%
Risk-Free Rate
Market Risk Premium
Cost of Equity 4.465
Total Debt -
Total Equity 84.44
Total Capital 84.44
Debt Weighting 0.00
Equity Weighting 100.00
Wacc

Build Up Free Cash Flow

Year
A/P
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Revenue ----------
Operating Cash Flow ----------
Capital Expenditure ----------
Free Cash Flow ----------
WACC
PV LFCF ----------
SUM PV LFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 4.46
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -5.40
Equity Value -
Shares Outstanding 29.63
Equity Value Per Share -